Safety and Efficacy of Short-Term Celecoxib Before Elective Percutaneous Coronary Intervention for Stable Angina Pectoris

American Journal of Cardiology

Volumn 98, Issue 11, 2006, Pages 1461-1463

  Pelliccia, Francesco ^a,b   Pasceri, Vincenzo ^a   Granatelli, Antonino ^a   Pristipino, Christian ^a   Speciale, Giulio ^a   Roncella, Adriana ^a   Cianfrocca, Cinzia ^a   Mercuro, Giuseppe ^b   Richichi, Giuseppe ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CREATINE KINASE; MYOGLOBIN; PLACEBO; TROPONIN I;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STABLE ANGINA PECTORIS;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CREATINE KINASE, MB FORM; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; MYOGLOBIN; PILOT PROJECTS; PYRAZOLES; STENTS; SULFONAMIDES; TROPONIN I;

EID: 33751188916     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.06.045     Document Type: Article

References (9)

1. Nallamothu B.K., and Bates E.R. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 42 (2003) 1412-1414
2. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of CK-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 42 (2003) 1406-1411
3. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., and Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. Circulation 110 (2004) 674-678
4. Uettwiller-Geiger D., Wu A.H., Apple F.S., Jevans A.W., Venge P., Olson M.D., Darte C., Woodrum D.L., Roberts S., and Chan S. Multicenter evaluation of an automated assay for troponin I. Clin Chem 48 (2002) 869-876
5. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36 (2000) 959-969
6. Wang K., Tarakji K., Zhou Z., Zhang M., Forudi F., Zhou X., Koki A.T., Smith M.E., Keller B.T., Topol E.J., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 45 (2005) 61-67
7. Walter D.H., Fichtlscherer S., Sellwig M., Auch-Schwelk W., Schachinger V., and Zeiher A.M. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37 (2001) 839-846
8. Andersohn F., Suissa S., and Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 113 (2006) 1950-1957
9. Burleigh M.E., Babaev V.R., Oates J.A., Harris R.C., Gautam S., Riendeau D., Marnett L.J., Morrow J.D., Fazio S., and Linton M.F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823